Citius Pharmaceuticals (CTXR) Competitors $1.40 +0.08 (+5.64%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. CRVO, STRO, ABVC, RPTX, ARTV, VTVT, UNCY, BYSI, VNRX, and ALTSShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include CervoMed (CRVO), Sutro Biopharma (STRO), ABVC BioPharma (ABVC), Repare Therapeutics (RPTX), Artiva Biotherapeutics (ARTV), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), BeyondSpring (BYSI), VolitionRx (VNRX), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors CervoMed Sutro Biopharma ABVC BioPharma Repare Therapeutics Artiva Biotherapeutics vTv Therapeutics Unicycive Therapeutics BeyondSpring VolitionRx ALT5 Sigma CervoMed (NASDAQ:CRVO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Which has more risk & volatility, CRVO or CTXR? CervoMed has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Does the media favor CRVO or CTXR? In the previous week, CervoMed had 3 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for CervoMed and 0 mentions for Citius Pharmaceuticals. CervoMed's average media sentiment score of 0.98 beat Citius Pharmaceuticals' score of 0.00 indicating that CervoMed is being referred to more favorably in the media. Company Overall Sentiment CervoMed Positive Citius Pharmaceuticals Neutral Is CRVO or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -290.72%. CervoMed's return on equity of -59.15% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-290.72% -59.15% -53.64% Citius Pharmaceuticals N/A -60.03%-33.83% Which has preferable valuation & earnings, CRVO or CTXR? CervoMed has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$9.74M8.28-$16.29M-$2.61-3.34Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Do analysts recommend CRVO or CTXR? CervoMed presently has a consensus target price of $19.29, suggesting a potential upside of 121.29%. Citius Pharmaceuticals has a consensus target price of $53.00, suggesting a potential upside of 3,672.24%. Given Citius Pharmaceuticals' higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than CervoMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60Citius Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do institutionals & insiders hold more shares of CRVO or CTXR? 25.2% of CervoMed shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCervoMed beats Citius Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.99M$2.63B$6.13B$10.51BDividend YieldN/A53.56%5.51%4.67%P/E RatioN/A24.0385.5226.80Price / SalesN/A603.97585.10183.02Price / CashN/A28.3526.3031.10Price / Book0.145.4713.166.63Net Income-$39.14M$32.78M$3.30B$276.44M7 Day Performance13.31%3.76%4.71%2.93%1 Month Performance14.23%9.35%8.36%9.95%1 Year Performance-85.77%-2.44%87.42%39.62% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.0636 of 5 stars$1.41+5.6%$53.00+3,672.2%-87.7%$23.99MN/A0.0020Gap UpCRVOCervoMed3.7084 of 5 stars$8.08-2.4%$19.29+138.7%-39.9%$76.61M$9.74M-3.104Short Interest ↓STROSutro Biopharma4.14 of 5 stars$0.88-1.3%$4.47+410.5%-75.9%$75.16M$62.04M-0.35240ABVCABVC BioPharma0.7764 of 5 stars$3.08-2.5%N/A+404.8%$74.39M$510K-18.1230Gap DownRPTXRepare Therapeutics2.8365 of 5 stars$1.74+3.0%$4.50+158.6%-50.9%$72.60M$53.48M-0.67180News CoveragePositive NewsARTVArtiva Biotherapeutics3.4507 of 5 stars$2.92-1.4%$17.00+482.2%-81.5%$72.30M$250K0.0081Positive NewsVTVTvTv Therapeutics1.7274 of 5 stars$22.88+2.5%$35.50+55.2%+54.8%$71.33M$1.02M-7.339UNCYUnicycive Therapeutics2.3386 of 5 stars$4.15+3.2%$57.00+1,273.5%+23.1%$71.00MN/A-1.019BYSIBeyondSpringN/A$1.74-1.1%N/A-24.9%$70.99M$1.75M0.0080Positive NewsVNRXVolitionRx2.2955 of 5 stars$0.62+3.0%$3.50+461.8%-27.0%$67.03M$1.32M-1.7380Gap UpALTSALT5 Sigma0.1051 of 5 stars$2.82-9.0%N/A+63.9%$66.99M$12.53M0.00170Short Interest ↑ Related Companies and Tools Related Companies CRVO Competitors STRO Competitors ABVC Competitors RPTX Competitors ARTV Competitors VTVT Competitors UNCY Competitors BYSI Competitors VNRX Competitors ALTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
